Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Skin Neoplasms × trametinib × Clear all

Phase

Status

Withdrawn 1 Terminated 1 Recruiting 1 No longer available 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 12 Carcinoma, Non-Small-Cell Lung 7 Neoplasms 5 Neoplasm Metastasis 4 Colorectal Neoplasms 3 Pancreatic Neoplasms 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Brain Neoplasms 2 Thrombocytosis 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1

Interventions

Cyclophosphamide 11 fludarabine 8 aldesleukin 8 fludarabine phosphate 6 pembrolizumab 5 Nivolumab 4 Ipilimumab 4 Interleukin-2 4 dabrafenib 2 Vemurafenib 2 Biopsy 2 Aminolevulinic Acid 2 varlilumab 1 trametinib 1 tilsotolimod 1 spartalizumab 1 sotigalimab 1 sonidegib 1 smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1 glembatumumab vedotin 1 eprenetapopt 1 encorafenib 1 cemiplimab 1 cabozantinib 1 binimetinib 1 bempegaldesleukin 1 abobotulinumtoxinA 1 X-Rays 1 Tranexamic Acid 1 Tacrolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02967692 2025-09-18

COMBI-i

Novartis

Phase 3 Terminated

568 enrolled 28 charts

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡